000910154 001__ 910154
000910154 005__ 20230123110657.0
000910154 0247_ $$2doi$$a10.2967/jnumed.121.262290
000910154 0247_ $$2ISSN$$a0022-3123
000910154 0247_ $$2ISSN$$a0097-9058
000910154 0247_ $$2ISSN$$a0161-5505
000910154 0247_ $$2ISSN$$a1535-5667
000910154 0247_ $$2ISSN$$a2159-662X
000910154 0247_ $$2Handle$$a2128/32636
000910154 0247_ $$2pmid$$a34326129
000910154 0247_ $$2WOS$$aWOS:000796182700014
000910154 037__ $$aFZJ-2022-03641
000910154 082__ $$a610
000910154 1001_ $$0P:(DE-HGF)0$$aDietlein, Felix$$b0
000910154 245__ $$aAn 89Zr-Labeled PSMA Tracer for PET/CT Imaging of Prostate Cancer Patients
000910154 260__ $$aNew York, NY$$bSoc.$$c2022
000910154 3367_ $$2DRIVER$$aarticle
000910154 3367_ $$2DataCite$$aOutput Types/Journal article
000910154 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1668668583_5418
000910154 3367_ $$2BibTeX$$aARTICLE
000910154 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000910154 3367_ $$00$$2EndNote$$aJournal Article
000910154 520__ $$aThe short half-life of existing prostate-specificmembraneantigen (PSMA) tracers limits their time for internalization into tumor cells after injection, which is an essential prerequisite for robust detection of tumor lesions with low PSMA expression on PET/CT scans. Because of its longer half-life, the 89Zr-labeled ligand 89Zr-PSMA-DFO allows acquisition of PET scans up to 6 d after injection, thereby overcoming the above limitation. We investigated whether 89Zr-PSMA-DFO allowed more sensitive detection of weak PSMA-positive prostate cancer lesions. Methods: We selected 14 prostate cancer patients with biochemical recurrence who exhibited no PSMA-positive lesions on a PET scan acquired with existing PSMA tracers (68Ga-PSMA-11, 18F-JK-PSMA-7). Within 5 wk after the negative scan result, we obtained a second PSMA PET scan using 89Zr-PSMA-DFO (117 6 16 MBq, PET acquisition within 6 d of injection). Results: 89Zr-PSMADFO detected 15 PSMA-positive lesions in 8 of 14 patients, who had a PET-negative reading of their initial PET scans with existing tracers. In these 8 patients, the new scans revealed localized recurrence of disease (3/8), metastases in lymph nodes (3/8), or lesions at distant sites (2/8). On the basis of these results, patients received lesiontargeted radiotherapies (5/8), androgen deprivation therapies (2/8), or no therapy (1/8). The plausibility of 14 of 15 lesions was supported by histology, clinical follow-up after radiotherapy, or subsequent imaging. Furthermore, comparison of the 15 89Zr-PSMA-DFO–positive lesions with their correlates on the original PET scan revealed that established tracers exhibited mild accumulation in 7 of 15 lesions; however, contrast-to-noise ratios were too low for robust detection of these lesions (contrast-to-noise ratios, 2.4 6 3.7 for established tracers vs. 10.2 6 8.5 for89Zr-PSMA-DFO, P 5 0.0014). The SUVmax of the 15 89ZrPSMA-DFO–positive lesions (11.5 6 5.8) was significantly higher than the SUVmax on the original PET scans (4.7 6 2.8, P5 0.0001). Kidneys were the most exposed organ, with doses of 3.3 6 0.7 mGy/MBq. The effective dose was 0.15 6 0.04 mSv/MBq. Conclusion: In patients with weak PSMA expression, a longer period of time might be needed for ligand internalization than that offered by existing PSMA tracers to make lesions visible on PET/CT scans. Hence, 89ZrPSMA-DFO might be of significant benefit to patients in whom the search for weak PSMA-positive lesions is challenging. Radiation exposure should be weighed against the potential benefitof metastasis-directed therapy or salvage radiotherapy, which weinitiated in 36% (5/14) of our patients based on their 89Zr-PSMA-DFO PET scans.
000910154 536__ $$0G:(DE-HGF)POF4-5253$$a5253 - Neuroimaging (POF4-525)$$cPOF4-525$$fPOF IV$$x0
000910154 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
000910154 7001_ $$0P:(DE-HGF)0$$aKobe, Carsten$$b1
000910154 7001_ $$0P:(DE-HGF)0$$aVázquez, Sergio Muñoz$$b2
000910154 7001_ $$0P:(DE-HGF)0$$aFischer, Thomas$$b3
000910154 7001_ $$0P:(DE-Juel1)180330$$aEndepols, Heike$$b4$$ufzj
000910154 7001_ $$0P:(DE-HGF)0$$aHohberg, Melanie$$b5
000910154 7001_ $$0P:(DE-HGF)0$$aReifegerst, Manuel$$b6
000910154 7001_ $$0P:(DE-Juel1)166419$$aNeumaier, Bernd$$b7$$ufzj
000910154 7001_ $$0P:(DE-HGF)0$$aSchomäcker, Klaus$$b8
000910154 7001_ $$0P:(DE-Juel1)177611$$aDrzezga, Alexander E.$$b9$$ufzj
000910154 7001_ $$0P:(DE-HGF)0$$aDietlein, Markus$$b10$$eCorresponding author
000910154 773__ $$0PERI:(DE-600)2040222-3$$a10.2967/jnumed.121.262290$$gVol. 63, no. 4, p. 573 - 583$$n4$$p573 - 583$$tJournal of nuclear medicine$$v63$$x0022-3123$$y2022
000910154 8564_ $$uhttps://juser.fz-juelich.de/record/910154/files/jnumed.121.262290.full.pdf$$yOpenAccess
000910154 909CO $$ooai:juser.fz-juelich.de:910154$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000910154 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)180330$$aForschungszentrum Jülich$$b4$$kFZJ
000910154 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)166419$$aForschungszentrum Jülich$$b7$$kFZJ
000910154 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)177611$$aForschungszentrum Jülich$$b9$$kFZJ
000910154 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5253$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
000910154 9141_ $$y2022
000910154 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-27
000910154 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-27
000910154 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000910154 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-27
000910154 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NUCL MED : 2021$$d2022-11-19
000910154 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-19
000910154 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-19
000910154 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-19
000910154 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-19
000910154 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-19
000910154 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-19
000910154 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-19
000910154 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bJ NUCL MED : 2021$$d2022-11-19
000910154 920__ $$lyes
000910154 9201_ $$0I:(DE-Juel1)INM-5-20090406$$kINM-5$$lNuklearchemie$$x0
000910154 9201_ $$0I:(DE-Juel1)INM-2-20090406$$kINM-2$$lMolekulare Organisation des Gehirns$$x1
000910154 980__ $$ajournal
000910154 980__ $$aVDB
000910154 980__ $$aUNRESTRICTED
000910154 980__ $$aI:(DE-Juel1)INM-5-20090406
000910154 980__ $$aI:(DE-Juel1)INM-2-20090406
000910154 9801_ $$aFullTexts